- Conditions
- Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
- Interventions
- Asundexian (BAY2433334), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12,327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 108
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 13,535
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bipolar Disorder
- Interventions
- Acupuncture
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
- Conditions
- Acute Pancreatitis (AP)
- Interventions
- Acute Pancreatitis
- Procedure
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- CRLX101, Bevacizumab, Standard of Care (Investigator Choice)
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 38
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Golimumab, Infliximab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 938 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Single intratumoral injection of DNX-2401, Interferon-gamma
- Drug
- Lead sponsor
- DNAtrix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Armodafinil
- Drug
- Lead sponsor
- Cephalon, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule
- Drug · Other
- Lead sponsor
- Corbus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 27
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
- Conditions
- Carotid Artery Disease
- Interventions
- Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Phoenix, Arizona + 94 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Interventions
- Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Acromegaly
- Interventions
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
- Conditions
- Low Back Pain, Low Back Pain, Recurrent
- Interventions
- JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg, JNJ-42160443 10 mg, Matching Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Hematological Malignancies
- Interventions
- Magrolimab, Azacitidine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 26
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Neurofibromatosis Type 2
- Interventions
- REC-2282, Placebo
- Drug
- Lead sponsor
- Recursion Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 8 more
- Conditions
- Hemophilia A
- Interventions
- FVIII concentrate
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
- Conditions
- Penetrating Trauma Registry and Open Source Data
- Interventions
- Treatment measures and intervention strategies
- Behavioral
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Preterm Birth
- Interventions
- Not listed
- Lead sponsor
- Luc Brion
- Other
- Eligibility
- 24 Weeks to 35 Weeks
- Enrollment
- 3,843 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- Investigators choice of SoC, AAA817
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin detemir, insulin glargine, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Vestavia Hills, Alabama • Little Rock, Arkansas + 60 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Gan & Lee Insulin Lispro Injection, Humalog
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 58
- States / cities
- Anaheim, California • Fresno, California • Los Angeles, California + 52 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Dalcetrapib, Placebo
- Drug
- Lead sponsor
- DalCor Pharmaceuticals
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 186
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more